α-受体阻滞剂是治疗良性前列腺增生症(BPH)的一线治疗药物。Kirby RS等通过一项为期20周的随机、双盲、交叉对照研究的数据,比较了多沙唑嗪控释片(GITS)与坦索罗辛治疗BPH的疗效。结果显示,经过8周的治疗,两种药物均显著改善了国际前列腺症状总评分(IPSS)及梗阻、刺激症状评分(P<0．001)。而多沙唑嗪控释片组比坦索罗辛组改善更为明显 Alpha-blockers are first-line therapies for the treatment of benign prostatic hyperplasia (BPH). Kirby RS et al. Compared the efficacy of doxazosin controlled-release tablets (GITS) with tamsulosin in the treatment of BPH through a 20-week randomized, double-blind, crossover study. The results showed that both drugs significantly improved the International Prostate Symptom Score (IPSS) and obstruction and irritation symptom scores (P <0.001) after 8 weeks of treatment. The doxazosin controlled-release tablets group than tamsulosin group to improve more obvious